Sera Prognostics appointed Mark Capone to its Board of Directors as a Class II director and to the Compensation Committee, effective July 1, 2026. Capone is a veteran healthcare executive with over 40 years of experience, including as former CEO of Myriad Genetics. He will receive standard non-employee director compensation, including an initial equity award with a grant date fair value of $167,072 and cash retainers. The company issued a press release on June 30, 2026 to announce the appointment.
Who are the top institutional investors holding SERA PROGNOSTICS INC-A (SERA)?
Major stakeholders currently include Baker Bros. Advisors LP ($11.2M), Whetstone Capital Advisors, LLC ($6.7M), Aberdeen Group plc ($5.2M). Based on the latest 13F filings, there are a total of 56 tracked investment funds and institutions maintaining positions in SERA.
What is the overall institutional sentiment toward SERA recently?
Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $11.5M, driven by 14 managers accumulating shares while 28 reduced their exposure.
Which institutions have been selling or reducing their SERA positions?
In the latest period, 17 funds trimmed their holdings, and 11 managers completely exited their positions. The aggregate reported sell value was $16.3M.
Are there any notable investors adding SERA to their portfolios?
Yes, buying activity remains notable. 8 institutions opened new positions in {ticker}, and 6 existing holders added to their shares. The total reported buy value for the quarter amounted to $12.2M.
Related Stocks
Trending Institutional Adds
The most-added stocks by 13F institutions this quarter